Stem cell collection and gene transfer in fanconi anemia

Molecular Therapy

Volumn 15, Issue 1, 2007, Pages 211-219

  Kelly, Patrick F ^a   Radtke, Susan ^a   von Kalle, Cristof ^a,b   Balcik, Brenden ^c   Bohn, Kimberley ^a   Mueller, Robin ^a   Schuesler, Todd ^a   Haren, Moira ^a   Reeves, Lilith ^a   Cancelas, Jose A ^a,c   Leemhuis, Thomas ^c   Harris, Richard ^a   Auerbach, Arleen D ^d   Smith, Franklin O ^a   Davies, Stella M ^a   Williams, David A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; RETROVIRUS VECTOR;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELL COMPARTMENTALIZATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EX VIVO STUDY; FANCONI ANEMIA; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; INFECTION; PANCYTOPENIA; PATIENT SAFETY; PHENOTYPE; STEM CELL GENE THERAPY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADOLESCENT; ANTIGENS, CD34; BONE MARROW; CELL SEPARATION; CHILD; CHILD, PRESCHOOL; DNA, COMPLEMENTARY; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; GENE THERAPY; HUMANS; INFANT; STEM CELLS; TRANSGENES;

EID: 33845993292     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300033     Document Type: Article

References (45)

1. Taniguchi, T and D'Andrea, AD (2006). Molecular pathogenesis of Fanconi anemia: Recent progress. Blood 107: 4223-4233.
2. Kutler, DI et al. (2003). A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101: 1249-1256.
3. Gluckman, E et al. (1995). Bone marrow transplantation for Fanconi anemia. Blood 86: 2856-2862.
4. Boyer, MW et al. (2003). Low risk of graft-versus-host disease with transplantation of CD34 selected peripheral blood progenitor cells from alternative donors for Fanconi anemia. J Pediatr Hematol Oncol 25: 890-895.
5. Korthof, ET et al. (2003). Haploidentical stem cell transplantation for severe aplastic anemia in Fanconi anemia. In: American Society of Hematology Annual Meeting. San Diego, CA.
6. Gluckman, E, Pasquini, R, Rocha, V and Harris, RE (2003). Results of unrelated cord blood transplants in Fanconi anemia. In: American Society of Hematology Annual Meeting. San Diego, CA.
7. Cavazzana-Calvo, M et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [see comments]. Science 288: 669-672.
8. Aiuti, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
9. Ott, MG et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
10. Hanenberg, H et al. (2002). Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp Hematol 30: 410-420.
11. Chandra, S et al. (2005). A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. Mol Ther 12: 976-984.
12. Marathi, UK, Howell, SR, Ashmun, RA and Brent, TP (1996). The Fanconi anemia complementation group C protein corrects DNA interstrand cross-link-specific apoptosis in HSC536N cells. Blood 88: 2298-2305.
13. Walsh, CE et al. (1994). A functionally active retrovirus vector for gene therapy in Fanconi anemia group C. Blood 84: 453-459.
14. Freie, BW, Dutt, P and Clapp, DW (1996). Correction of Fanconi anemia type C phenotypic abnormalities using a clinically suitable retroviral vector infection protocol. Cell Transplant 5: 385-393.
15. Waisfisz, Q et al. (1999). A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA. Proc Natl Acad Sci USA 96: 10320-10325.
16. Gregory, JJ, Jr et al. (2001). Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA 98: 2532-2537.
17. Gross, M et al. (2002). Reverse mosaicism in Fanconi anemia: Natural gene therapy via molecular self-correction. Cytogenet Genome Res 98: 126-135.
18. Mankad, A et al. (2006). Natural gene therapy in monozygotic twins with Fanconi anemia. Blood 107: 3084-3090.
19. Bagby, GC, Jr (2003). Genetic basis of Fanconi anemia. Curr Opin Hematol 10: 68-76.
20. Kennedy, RD and D'Andrea, AD (2005). The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev 19: 2925-2940.
21. Koh, PS, Hughes, GC, Faulkner, GR, Keeble, WW and Bagby, GC (1999). The Fanconi anemia group C gene product modulates apoptotic responses to tumor necrosis factor-alpha and Fas ligand but does not suppress expression of receptors of the tumor necrosis factor receptor superfamily. Exp Hematol 27: 1-8.
22. Haneline, LS et al. (1998). Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood 91: 4092-4098.
23. Pang, P, Meathrel, K and Ko, K (1997). A component of the chloroplast protein import apparatus functions in bacteria. J Biol Chem 272: 25623-25627.
24. Rosselli, F, Sanceau, J, Gluckman, E, Wietzerbin, J and Moustacchi, E (1994). Abnormal lymphokine production: A novel feature of the genetic disease Fanconi Anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. Blood 83: 1216-1225.
25. Schultz, JC and Shahidi, NT (1993). Tumor necrosis factor-alpha overproduction in Fanconi's anemia. Am J Hematol 42: 196-201.
26. Haneline, LS et al. (2003). Retroviral-mediated expression of recombinant Fancc enhances the repopulating ability of Fancc-/- hematopoietic stem cells and decreases the risk of clonal evolution. Blood 101: 1299-1307.
27. Liu, SM et al. (1999). Engraftment of hematopoietic progenator cells transduced with Fancori anemia group ligand (FANCC). Human Gene Therapy 10: 2337-2346.
28. Auerbach, AD et al. (1990). Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia. Transfusion 30: 682-687.
29. Croop, JM et al. (2001). Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. Blood 98: 2917-2921.
30. Broxmeyer, HE et al. (2005). Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201: 1307-1318.
31. Liles, WC et al. (2003). Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102: 2728-2730.
32. Bodine, DM, Seidel, NE and Orlic, D (1996). Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow. Blood 88: 89-97.
33. Dunbar, CE et al. (1996). Improved retroviral gene transfer into murine and rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 93: 11871-11876.
34. Gaspar, HB et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
35. Christopherson, KW, II, Hangoc, G, Mantel, CR and Broxmeyer, HE (2004). Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305: 1000-1003.
36. Beslu, N et al. (2004). Molecular interactions involved in HOXB4-induced activation of HSC self-renewal. Blood 104: 2307-2314.
37. Ghiaur, G et al. (2006). Inhibition of RhoA GTPase activity enhances hematopoietic stem and progenitor cell proliferation and engraftment in vivo. Blood 108: 2087-2094.
38. Galla, M, Will, E, Kraunus, J, Chen, L and Baum, C (2004). Retroviral pseudotransduction for targeted cell manipulation. Mol Cell 16: 309-315.
39. Sutherland, DR, Anderson, L, Keeney, M, Nayar, R and Chin-Yee, I (1996). The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 5: 213-226.
40. Pollok, KE et al. (2003). In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther 14: 1703-1714.
41. Cheng, L et al. (1998). Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. Blood 92: 83-92.
42. Miller, AD et al. (1991). Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 65: 2220-2224.
43. Hanenberg, H et al. (1997). Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther 8: 2193-2206.
44. Cornetta, K et al. (2006). A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase. Cancer Gene Ther 13: 886-895.
45. Chen, J, Reeves, L and Cornetta, K (2001). Safety testing for replication-competent retrovirus associated with Gibbon Ape Leukemia virus-pseudotyped retroviral vectors. Hum Gene Ther 12: 61-70.